ReviewWorld journal of urology2019
Molecular markers in bladder cancer.
Review in World journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04872036 (Investigation of Prognostic Biomarkers in Patients With Urothelial Carcinoma Treated With Platinum Regimens), which is not on this map. Cited by 68 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigation of Prognostic Biomarkers in Patients With Urothelial Carcinoma Treated With Platinum Regimens
Who cites it
68 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review.PharmacoEconomics · 2023Pooled it
- Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis.BioMed research international · 2021Pooled it
- A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma.BJU international · 2022Trial
- Matrix Metalloproteinases and Pro-Inflammatory Cytokines in Bladder Cancer: Diagnostic and Prognostic Perspectives: Narrative Review.International journal of molecular sciences · 2026Review
- Article
- Multi-omics integration of molecular genetics, cytogenetics and immunophenotyping: a novel prognostic model for immune landscape characterization and outcome prediction in Chinese patients with acute myeloid leukemia.Frontiers in immunology · 2026Article
- Risk Stratification Using a Perioperative Nomogram for Predicting the Mortality of Bladder Cancer Patients Undergoing Radical Cystectomy.Journal of clinical medicine · 2025Article
- Biomarkers for predicting bladder cancer therapy response.Oncology research · 2025Review
- An unfolded protein response (UPR)-signature regulated by the NFKB-miR-29b/c axis fosters tumor aggressiveness and poor survival in bladder cancer.Frontiers in molecular biosciences · 2025Article
- Epigenetic dysregulation-induced metabolic reprogramming fuels tumor progression in bladder cancer.Frontiers in molecular biosciences · 2025Article
- Advances in Liquid Biopsy for Diagnosis of Bladder Cancer.International neurourology journal · 2024Article
- Article
- Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers.International journal of molecular sciences · 2023Review
- Comparative proteomics analysis in different stages of urothelial bladder cancer for identification of potential biomarkers: highlighted role for antioxidant activity.Clinical proteomics · 2023Article
- Immunohistochemical expressions of EMT markers in pan-RAS-pERK1/2-positive tumors improve diagnosis and prognosis assessment of non-muscle invasive bladder cancer and muscle invasive bladder cancer patients.Molecular and cellular biochemistry · 2023Article
- Sarcopenia Predicts Disease Progression in Patients with T1 High-grade Non-muscle-invasive Bladder Cancer Treated with Adjuvant Intravesical Bacillus Calmette-Guérin: Implications for Decision-making?European urology open science · 2023Article
- Targeting the anaphase-promoting complex/cyclosome (APC/C) enhanced antiproliferative and apoptotic response in bladder cancer.Saudi journal of biological sciences · 2023Article
- Rapid Detection of Recurrent Non-Muscle Invasive Bladder Cancer in Urine Using ATR-FTIR Technology.Molecules (Basel, Switzerland) · 2022Article
- State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer.Biosensors · 2022Review
- The value of BCL2 and CK20 expression in predicting behavioral patterns of bladder cancer, a cross sectional study.Annals of medicine and surgery (2012) · 2022Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUse of molecular markers in urine, tissue or blood offers potential opportunities to improve understanding of bladder cancer biology which may help identify disease earlier, risk stratify patients, improve prediction of outcomes or help target therapy.
methodsA review of the published literature was performed, without restriction of time.
resultsDespite the fast-growing literature about the topic and the approval of several urinary biomarkers for use in clinical practice, they have not reached the level of evidence for widespread utilization. Biomarkers could be used in different clinical scenarios, mainly to overcome the limitations of current diagnostic, predictive, and prognostic tools. They have been evaluated to detect bladder cancer in asymptomatic populations or those with hematuria and in surveillance of disease as adjuncts to cystoscopy. There is also a potential role as prognosticators of disease recurrence, progression and survival both in patients with non-invasive cancers and in those with advanced disease. Finally, they promise to be helpful in predicting the response to local and/or systemic chemotherapy and/or immunotherapy.
conclusionsTo date, due to the lack of high-quality prospective trials, the level of evidence provided by the current literature remains low and, therefore, the potential of biomarkers exceeds utilization in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.